
AbCellera Biologics Inc. (NASDAQ:ABCL) (&#34;AbCellera&#34;) today announced that it has commenced an underwritten public offering of $200.0 million of its common shares and, in lieu of common shares to certain

<p xmlns="http://www.w3.org/1999/xhtml">
AbCellera Biologics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/ABCL">ABCL</a>) ("AbCellera") today announced that it has commenced an underwritten public offering of $200.0 million of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares. All of the common shares and pre-funded warrants are being offered by AbCellera. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

</p><p xmlns="http://www.w3.org/1999/xhtml">
AbCellera intends to use the net proceeds from the offering to fund the continued research, development and clinical advancement of its internal pipeline, including its lead clinical program, ABCL635, as well as for working capital and other general corporate purposes.

</p><p xmlns="http://www.w3.org/1999/xhtml">
Jefferies, J.P. Morgan, Cantor, UBS Investment Bank, and BMO Capital Markets are acting as joint book-running managers for the proposed offering.

</p><p xmlns="http://www.w3.org/1999/xhtml">
The securities described above are being offered pursuant to a shelf registration statement on Form S-3ASR (No. 333-285367) that was filed with the U.S. Securities and Exchange Commission (the "SEC") on February 27, 2025 and automatically became effective upon filing. This proposed offering is being made only by means of a prospectus supplement and an accompanying prospectus that form a part of the registration statement. A preliminary prospectus supplement related to and describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov. Copies of the preliminary prospectus supplement and an accompanying prospectus related to the proposed offering may also be obtained, when available, from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; Cantor Fitzgerald &amp; Co., Attention: Capital Markets, 110 East 59<sup xmlns="http://www.w3.org/1999/xhtml">th</sup> Street, 6<sup xmlns="http://www.w3.org/1999/xhtml">th</sup> Floor, New York, NY 10022, or by email at prospectus@cantor.com; UBS Securities LLC, Attention: Prospectus Department, 11 Madison Avenue, New York, NY 10010, by email at ol-prospectus-request@ubs.com; or BMO Capital Markets Corp., Attn: Equity Syndicate Department, 151 W 42nd Street, 32nd Floor, New York, NY 10036, or by email at bmoprospectus@bmo.com.

</p><p xmlns="http://www.w3.org/1999/xhtml">
No securities are being offered or sold, directly or indirectly, in Canada or to any resident of Canada.

</p><p xmlns="http://www.w3.org/1999/xhtml">
This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">About AbCellera Biologics Inc.</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
AbCellera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/ABCL">ABCL</a>) is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody-based medicines in the areas of endocrinology, women’s health, immunology, oncology, and more.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">AbCellera Forward-looking Statements</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
This document contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this document other than statements of historical fact are forward-looking statements, including statements regarding the size and expected proceeds from the proposed offering, completion and timing of the proposed offering, and the anticipated use of proceeds from the proposed offering. In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.

</p><p xmlns="http://www.w3.org/1999/xhtml">
These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties, other factors, and definition of our business metrics are described under "Risk Factors," "Management’s Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the SEC from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this document represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

</p><p xmlns="http://www.w3.org/1999/xhtml"><img xmlns="http://www.w3.org/1999/xhtml" alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260811173370r1&amp;sid=benz2&amp;distro=nx&amp;lang=en" style="width:0;height:0"></img><span xmlns="http://www.w3.org/1999/xhtml" class="bwct31415"></span></p><p xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink"><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-phrase">View source version on businesswire.com: </span><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-link"><a xmlns="http://www.w3.org/1999/xhtml" href="https://www.businesswire.com/news/home/20260811173370/en/" rel="nofollow">https://www.businesswire.com/news/home/20260811173370/en/</a></span></p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Inquiries 
</b><br xmlns="http://www.w3.org/1999/xhtml"></br>Media: Tiffany Chiu; media@abcellera.com, +1(236)521-6774
<br xmlns="http://www.w3.org/1999/xhtml"></br>Partnering: Murray McCutcheon, Ph.D.; partnering@abcellera.com, +1(604)559-9005
<br xmlns="http://www.w3.org/1999/xhtml"></br>Investor Relations: Peter Ahn; ir@abcellera.com, +1(778)729-9116

</p>

ABCL

AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

AbCellera launches $200M equity offering to fund ABCL635 and pipeline

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>AbCellera Biologics Inc. (NASDAQ:ABCL) (&amp;#34;AbCellera&amp;#34;) today announced that it has commenced an underwritten public offering of $200.0 million of its common shares and, in lieu of common shares to certain</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>AbCellera Biologics announced an underwritten public offering of $200 million in common shares and pre-funded warrants to fund its internal pipeline, including ABCL635, and general corporate needs. Proceeds will support ongoing research, development and clinical advancement, with Jefferies, J.P. Morgan, Cantor, UBS, and BMO acting as book-running managers. The deal is conditional and not guaranteed to close, pending market conditions.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>AbCellera launches $200M public offering of common shares and pre-funded warrants.</li><li>Proceeds to fund internal pipeline, including ABCL635, plus working capital.</li><li>Joint book-running managers: Jefferies, J.P. Morgan, Cantor, UBS, BMO.</li><li>Shelf registration Form S-3ASR No. 333-285367; filed Feb 27, 2025; effective upon filing.</li><li>Offering subject to market conditions; no guaranteed completion or terms.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>AbCellera Biologics Inc. (ABCL)</strong>: Issuer; potential dilution and utilization of proceeds to fund ABCL635 and pipeline advancement.</li><li><strong>J.P. Morgan Chase &amp; Co. (JPM)</strong>: Underwriter; involvement signals financing scale and pricing support.</li><li><strong>Jefferies Financial Group Inc. (JEF)</strong>: Underwriter; participates in book-running responsibilities.</li><li><strong>Cantor Fitzgerald &amp; Co. (Cantor (private))</strong>: Underwriter; private firm, participation signals syndicate strength.</li><li><strong>UBS Group AG (UBS)</strong>: Underwriter; large-cap bank involvement.</li><li><strong>Bank of Montreal (BMO)</strong>: Underwriter; confirms U.S. market syndicate coverage.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>Financing-related corporate development; highlights ABCL&#039;s capital-raise to support internal programs and pipeline milestones, with near-term dilution risk but potential long-term value if proceeds accelerate ABCL635 and other programs.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Immediate dilution risk may weigh on ABCL stock in the near term.</li><li>Use of proceeds toward ABCL635 could unlock upside if milestones are achieved.</li><li>Shelf registration implies potential future issuances beyond the current offering.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Offering amount: $200.0 million.</li><li>Use of proceeds: internal pipeline (ABCL635) and working capital.</li><li>Joint book-running managers: Jefferies, J.P. Morgan, Cantor Fitzgerald, UBS, BMO.</li><li>Shelf registration Form S-3ASR No. 333-285367; filed Feb 27, 2025; effective upon filing.</li><li>No securities offered in Canada.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Near-term dilution likely pressure ABCL shares until proceeds enable pipeline milestones.</p>
  </section>
</section>


<p xmlns="http://www.w3.org/1999/xhtml">
AbCellera Biologics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/ABCL">ABCL</a>) ("AbCellera") today announced that it has commenced an underwritten public offering of $200.0 million of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares. All of the common shares and pre-funded warrants are being offered by AbCellera. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

</p><p xmlns="http://www.w3.org/1999/xhtml">
AbCellera intends to use the net proceeds from the offering to fund the continued research, development and clinical advancement of its internal pipeline, including its lead clinical program, ABCL635, as well as for working capital and other general corporate purposes.

</p><p xmlns="http://www.w3.org/1999/xhtml">
Jefferies, J.P. Morgan, Cantor, UBS Investment Bank, and BMO Capital Markets are acting as joint book-running managers for the proposed offering.

</p><p xmlns="http://www.w3.org/1999/xhtml">
The securities described above are being offered pursuant to a shelf registration statement on Form S-3ASR (No. 333-285367) that was filed with the U.S. Securities and Exchange Commission (the "SEC") on February 27, 2025 and automatically became effective upon filing. This proposed offering is being made only by means of a prospectus supplement and an accompanying prospectus that form a part of the registration statement. A preliminary prospectus supplement related to and describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov. Copies of the preliminary prospectus supplement and an accompanying prospectus related to the proposed offering may also be obtained, when available, from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; Cantor Fitzgerald &amp; Co., Attention: Capital Markets, 110 East 59<sup xmlns="http://www.w3.org/1999/xhtml">th</sup> Street, 6<sup xmlns="http://www.w3.org/1999/xhtml">th</sup> Floor, New York, NY 10022, or by email at prospectus@cantor.com; UBS Securities LLC, Attention: Prospectus Department, 11 Madison Avenue, New York, NY 10010, by email at ol-prospectus-request@ubs.com; or BMO Capital Markets Corp., Attn: Equity Syndicate Department, 151 W 42nd Street, 32nd Floor, New York, NY 10036, or by email at bmoprospectus@bmo.com.

</p><p xmlns="http://www.w3.org/1999/xhtml">
No securities are being offered or sold, directly or indirectly, in Canada or to any resident of Canada.

</p><p xmlns="http://www.w3.org/1999/xhtml">
This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">About AbCellera Biologics Inc.</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
AbCellera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/ABCL">ABCL</a>) is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody-based medicines in the areas of endocrinology, women’s health, immunology, oncology, and more.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">AbCellera Forward-looking Statements</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
This document contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this document other than statements of historical fact are forward-looking statements, including statements regarding the size and expected proceeds from the proposed offering, completion and timing of the proposed offering, and the anticipated use of proceeds from the proposed offering. In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.

</p><p xmlns="http://www.w3.org/1999/xhtml">
These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties, other factors, and definition of our business metrics are described under "Risk Factors," "Management’s Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the SEC from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this document represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

</p><p xmlns="http://www.w3.org/1999/xhtml"><img xmlns="http://www.w3.org/1999/xhtml" alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260811173370r1&amp;sid=benz2&amp;distro=nx&amp;lang=en" style="width:0;height:0"></img><span xmlns="http://www.w3.org/1999/xhtml" class="bwct31415"></span></p><p xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink"><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-phrase">View source version on businesswire.com: </span><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-link"><a xmlns="http://www.w3.org/1999/xhtml" href="https://www.businesswire.com/news/home/20260811173370/en/" rel="nofollow">https://www.businesswire.com/news/home/20260811173370/en/</a></span></p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Inquiries 
</b><br xmlns="http://www.w3.org/1999/xhtml"></br>Media: Tiffany Chiu; media@abcellera.com, +1(236)521-6774
<br xmlns="http://www.w3.org/1999/xhtml"></br>Partnering: Murray McCutcheon, Ph.D.; partnering@abcellera.com, +1(604)559-9005
<br xmlns="http://www.w3.org/1999/xhtml"></br>Investor Relations: Peter Ahn; ir@abcellera.com, +1(778)729-9116

</p>

AbCellera Biologics announced an underwritten public offering of $200 million in common shares and pre-funded warrants to fund its internal pipeline, including ABCL635, and general corporate needs. Proceeds will support ongoing research, development and clinical advancement, with Jefferies, J.P. Morgan, Cantor, UBS, and BMO acting as book-running managers. The deal is conditional and not guaranteed to close, pending market conditions.

News insight

AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

AI summary

Sentiment rationale

Key facts

Corporate Developments